Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542564 | 0.86 | LMNA (0.64) | LMNAKMT2AMEN1ADAM17 | |
| SCHEMBL542810 | 0.79 | LMNA (0.56) | LMNAPDE4BPDE4DKMT2AMEN1 | |
| SCHEMBL542606 | 0.78 | MEN1 (0.64) | LMNAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL1092702 | 0.77 | MEN1 (0.47) | LMNAPDE4BPDE4DKMT2AMEN1 | |
| SCHEMBL1968434 | 0.77 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17 | |
| SCHEMBL29688389 | 0.77 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17 | |
| SCHEMBL20135360 | 0.77 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17 | |
| SCHEMBL542150 | 0.77 | LMNA (0.59) | LMNAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL542399 | 0.75 | MEN1 (0.64) | LMNAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL20134874 | 0.74 | LMNA (0.56) | LMNAKMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | LMNA 1674/4885PDE4B 3198/4885PDE4D 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.